NeuBase Therapeutics, Inc.

DB:O7P Voorraadrapport

Marktkapitalisatie: €1.3m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

NeuBase Therapeutics Beheer

Beheer criteriumcontroles 1/4

We currently do not have sufficient information about the CEO.

Belangrijke informatie

Todd Branning

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEO2.4yrs
Eigendom CEO0.04%
Management gemiddelde ambtstermijngeen gegevens
Gemiddelde ambtstermijn bestuur3.6yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Todd Branning's beloning veranderd ten opzichte van NeuBase Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Mar 31 2023n/an/a

-US$25m

Dec 31 2022n/an/a

-US$30m

Sep 30 2022US$922kUS$311k

-US$34m

Compensatie versus markt: Insufficient data to establish whether Todd's total compensation is reasonable compared to companies of similar size in the German market.

Compensatie versus inkomsten: Insufficient data to compare Todd's compensation with company performance.

CEO

Todd Branning (54 yo)

2.4yrs

Tenure

US$922,445

Compensatie

Mr. Todd P. Branning serves as an Interim Chief Executive Officer since January 16, 2024 and Chief Financial Officer of NeuBase Therapeutics, Inc. since January 2022 and serves as its Secretary. He joined...

Bestuursleden

NaamPositieTenureCompensatieEigendom
Dietrich Stephan
Founder4.9yrsUS$1.15m6.14%
€ 78.5k
Dov Goldstein
Independent Chairperson4.9yrsUS$74.42k0.040%
€ 510.9
Eric Richman
Independent Director4.9yrsUS$68.38k0.060%
€ 765.3
George Church
Chairperson of Gene Editing Advisory Board & Member of Scientific Advisory Board1.1yrsgeen gegevensgeen gegevens
Steven Dowdy
Member of Gene Editing & Scientific Advisory Board4.7yrsgeen gegevensgeen gegevens
James Coull
Member of Gene Editing Advisory Board1.1yrsgeen gegevensgeen gegevens
Randy Davis
Member of Scientific Advisory Board3.6yrsgeen gegevensgeen gegevens
Danith Ly
Member of Advisory Boardno datageen gegevensgeen gegevens
Robert Friedlander
Chair of Scientific Advisory Boardno datageen gegevensgeen gegevens
Peter Nielsen
Member of Gene Editing & Scientific Advisory Board3.7yrsgeen gegevensgeen gegevens
Eriks Rozners
Member of Gene Editing & Scientific Advisory Board3.6yrsgeen gegevensgeen gegevens
Gerald Mcdougall
Independent Director3.1yrsUS$59.79k0%
€ 0

3.6yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren bestuur: O7P's board of directors are considered experienced (3.6 years average tenure).